FindTrial
Sign In

The Efficacy of Traditional Chinese Medicine Syndrome Differentiation Treatment for COVID 19 Patients: a Non-Randomized Controlled Study

The Efficacy of Traditional Chinese Medicine Syndrome Differentiation Treatment for COVID 19 Patients: a Non-Randomized Controlled Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005848
Enrollment
Unknown
Registered
2022-04-11
Start date
2022-04-11
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid 19

Interventions

control group:Routine Western Medicine
experimental group:TCM Syndrome Differentiation Treatment

Sponsors

The Affiliated Hospital to Changchun University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients should meet the diagnostic criteria for mild and common patients with COVID 19 in China's "COVID 19 diagnosis and treatment program (Trial Ninth Version)"; 2.Aged 18 to 60 years.

Exclusion criteria

Exclusion criteria: 1. Pregnant women, women with a positive urine pregnancy test, and lactating women; 2. Patients whose hospitalization medical information cannot be obtained; 3. Patients with allergic history record to traditional Chinese medicine.

Design outcomes

Secondary

MeasureTime frame
Symptom disappearance rate;Nucleic acid negative time;Hospitalization time;Fever reduction time;Symptom disappearance time;Severe rate;—

Countries

China

Contacts

Public ContactWang Tan

The Affiliated Hospital to Chagnchun University of Chinese Medicine

1357979767@qq.com+86 13756858523

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026